Eilsberger Friederike, Luster Markus, Reiners Christoph
Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany.
Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Front Nucl Med. 2022 Jan 21;1:797522. doi: 10.3389/fnume.2021.797522. eCollection 2021.
Radioiodine therapy (RAI) is usually a standard procedure performed after thyroidectomy in differentiated thyroid cancer (DTC). While the indication for RAI in high-risk patients has been established in various national and international guidelines, there is an ongoing discussion with regard to intermediate-risk patients. In addition to the inconsistent definition of this risk category, the absence of large multinational prospective randomized controlled trials forms the basis of the debate. In this context, the actual pattern of care and national guidelines in the country where the patient is living plays an important role with respect to regional iodine supply and goiter prevalence, preoperative diagnostics (fine needle aspiration biopsy), and corresponding surgical strategies. Participatory decision-making between physician and informed patient, which is demanded in principle today anyway, is of particular importance in this situation. This article will discuss the approach of shared decision making for radioiodine therapy in intermediate-risk DTC.
放射性碘治疗(RAI)通常是分化型甲状腺癌(DTC)甲状腺切除术后的标准治疗程序。虽然高风险患者接受RAI治疗的指征已在各种国家和国际指南中确立,但对于中风险患者仍在进行讨论。除了这一风险类别的定义不一致外,缺乏大型跨国前瞻性随机对照试验也是辩论的基础。在这种情况下,患者所在国家的实际医疗模式和国家指南在区域碘供应和甲状腺肿患病率、术前诊断(细针穿刺活检)以及相应的手术策略方面起着重要作用。医生与知情患者之间的共同决策,无论如何这在当今原则上都是必需的,在这种情况下尤为重要。本文将讨论中风险DTC放射性碘治疗的共同决策方法。